Rieckert Anja, Becker Annette, Donner-Banzhof Norbert, Viniol Annika, Bücker Bettina, Wilm Stefan, Sönnichsen Andreas, Barzel Anne
Institute of General Practice and Family Medicine, Faculty of Health, Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany.
Department of General Medicine, Preventive and Rehabilitation Medicine, University of Marburg, Karl-von-Frisch Str. 4, 35043, Marburg, Germany.
Trials. 2019 Nov 21;20(1):636. doi: 10.1186/s13063-019-3728-2.
Proton pump inhibitors (PPIs) are increasingly being prescribed, although long-term use is associated with multiple side effects. Therefore, an electronic decision support tool with the aim of reducing the long-term use of PPIs in a shared decision-making process between general practitioners (GPs) and their patients has been developed. The developed tool is a module that can be added to the so-called arriba decision support tool, which is already used by GPs in Germany in routine care. In this large-scale cluster-randomized controlled trial we evaluate the effectiveness of this arriba-PPI tool.
The arriba-PPI tool is an electronic decision support system that supports shared decision-making and evidence-based decisions around the long-term use of PPIs at the point of care. The tool will be evaluated in a cluster-randomized controlled trial involving 210 GP practices and 3150 patients in Germany. GP practices will be asked to recruit 20 patients aged ≥ 18 years regularly taking PPIs for ≥ 6 months. After completion of patient recruitment, each GP practice with enrolled patients will be cluster-randomized. Intervention GP practices will get access to the software arriba-PPI, whereas control GPs will treat their patients as usual. After an observation period of six months, GP practices will be compared regarding the reduction of cumulated defined daily doses of PPI prescriptions per patient.
Our principal hypothesis is that the application of the arriba-PPI tool can reduce PPI prescribing in primary care by at least 15% compared to conventional strategies used by GPs. A positive result implies the implementation of the arriba-PPI tool in routine care.
German Clinical Trials Register, DRKS00016364. Registered on 31 January 2019.
质子泵抑制剂(PPIs)的处方量日益增加,尽管长期使用会带来多种副作用。因此,已开发出一种电子决策支持工具,旨在在全科医生(GPs)与其患者之间的共同决策过程中减少PPIs的长期使用。所开发的工具是一个模块,可以添加到所谓的arriba决策支持工具中,德国的全科医生已在日常护理中使用该工具。在这项大规模整群随机对照试验中,我们评估了这种arriba-PPI工具的有效性。
arriba-PPI工具是一种电子决策支持系统,可在医疗点围绕PPIs的长期使用支持共同决策和基于证据的决策。该工具将在一项整群随机对照试验中进行评估,该试验涉及德国的210家全科医生诊所和3150名患者。将要求全科医生诊所招募20名年龄≥18岁、定期服用PPIs≥6个月的患者。完成患者招募后,每个招募了患者的全科医生诊所将进行整群随机分组。干预组的全科医生诊所将可以使用arriba-PPI软件,而对照组的全科医生将照常治疗他们的患者。经过六个月的观察期后,将比较各全科医生诊所在减少每位患者PPI处方累计限定日剂量方面的情况。
我们的主要假设是,与全科医生使用的传统策略相比,应用arriba-PPI工具可使初级保健中PPI的处方量减少至少15%。积极的结果意味着将arriba-PPI工具应用于日常护理。
德国临床试验注册中心,DRKS00016364。于2019年1月31日注册。